The U.S. Food and Drug Administration (FDA) has announced that Risk Evaluation and Mitigation Strategies (REMS) will no longer be required for BCMA- and CD19-directed autologous CAR T cell...

ASTCT Submits Recommendations to OMB to Improve Access to Stem Cell and Cellular Therapies
 

CMS Transmittal on the National Coverage Decision for MDS

ASTCT Weighs in on Medicare Cuts in Funding Bill

The ASTCT Committee on Payer Relations has updated its standardized Request for Information (RFI) forms for 2025. 

ASTCT submitted comments and codes to CMS as part of the Interim Final OPPS Rule for Caregiver Training Services (CTS).